Nakagawa et al., 2016 - Google Patents
X-ray computed tomography imaging of a tumor with high sensitivity using gold nanoparticles conjugated to a cancer-specific antibody via polyethylene glycol chains …Nakagawa et al., 2016
View HTML- Document ID
- 3950229782245806980
- Author
- Nakagawa T
- Gonda K
- Kamei T
- Cong L
- Hamada Y
- Kitamura N
- Tada H
- Ishida T
- Aimiya T
- Furusawa N
- Nakano Y
- Ohuchi N
- Publication year
- Publication venue
- Science and Technology of advanced MaTerialS
External Links
Snippet
Contrast agents are often used to enhance the contrast of X-ray computed tomography (CT) imaging of tumors to improve diagnostic accuracy. However, because the iodine-based contrast agents currently used in hospitals are of low molecular weight, the agent is rapidly …
- 206010028980 Neoplasm 0 title abstract description 134
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
- A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
- A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
- A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
- A61K49/0409—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is not a halogenated organic compound
- A61K49/0414—Particles, beads, capsules or spheres
- A61K49/0423—Nanoparticles, nanobeads, nanospheres, nanocapsules, i.e. having a size or diameter smaller than 1 micrometer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
- A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
- A61K47/48769—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the conjugate being characterized by a special physical or galenical form
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Nakagawa et al. | X-ray computed tomography imaging of a tumor with high sensitivity using gold nanoparticles conjugated to a cancer-specific antibody via polyethylene glycol chains on their surface | |
| Chen et al. | Anti-HER2 antibody and ScFvEGFR-conjugated antifouling magnetic iron oxide nanoparticles for targeting and magnetic resonance imaging of breast cancer | |
| Hoshyar et al. | The effect of nanoparticle size on in vivo pharmacokinetics and cellular interaction | |
| Reuveni et al. | Targeted gold nanoparticles enable molecular CT imaging of cancer: an in vivo study | |
| Korchinski et al. | Iron oxide as an MRI contrast agent for cell tracking: supplementary issue | |
| Zhou et al. | Artificial local magnetic field inhomogeneity enhances T 2 relaxivity | |
| Cortajarena et al. | Engineering iron oxide nanoparticles for clinical settings | |
| Leuschner et al. | LHRH-conjugated magnetic iron oxide nanoparticles for detection of breast cancer metastases | |
| Mikhaylov et al. | Ferri-liposomes as an MRI-visible drug-delivery system for targeting tumours and their microenvironment | |
| Von Maltzahn et al. | Nanoparticles that communicate in vivo to amplify tumour targeting | |
| Hsieh et al. | In vivo tumor targeting and imaging with anti-vascular endothelial growth factor antibody-conjugated dextran-coated iron oxide nanoparticles | |
| Chen et al. | Folic acid-conjugated MnO nanoparticles as a T 1 contrast agent for magnetic resonance imaging of tiny brain gliomas | |
| Mu et al. | EGFR-targeted delivery of DOX-loaded Fe3O4@ polydopamine multifunctional nanocomposites for MRI and antitumor chemo-photothermal therapy | |
| Chen et al. | Plectin-1 targeted dual-modality nanoparticles for pancreatic cancer imaging | |
| Viswanath et al. | Recent insights into nanotechnology development for detection and treatment of colorectal cancer | |
| Wang et al. | Bio-functionalized dense-silica nanoparticles for MR/NIRF imaging of CD146 in gastric cancer | |
| Zhang et al. | In vivo tomographic imaging with fluorescence and MRI using tumor-targeted dual-labeled nanoparticles | |
| Karageorgis et al. | An MRI-based classification scheme to predict passive access of 5 to 50-nm large nanoparticles to tumors | |
| Zhao et al. | A GPC3-specific aptamer-mediated magnetic resonance probe for hepatocellular carcinoma | |
| Qin et al. | Noninvasive detection of macrophages in atherosclerotic lesions by computed tomography enhanced with PEGylated gold nanoparticles | |
| Edge et al. | Pharmacokinetics and bio‐distribution of novel super paramagnetic iron oxide nanoparticles (SPION s) in the anaesthetized pig | |
| Antonelli et al. | Red blood cells as carriers in magnetic particle imaging | |
| Aghighi et al. | Imaging tumor necrosis with ferumoxytol | |
| Liu et al. | A concise review of magnetic resonance molecular imaging of tumor angiogenesis by targeting integrin αvβ3 with magnetic probes | |
| Morris et al. | Nanotechnologies in cancer treatment and diagnosis |